Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Carcinosarcoma 1

Interventions

Cisplatin 23Magnetic Resonance Spectroscopy 18Gemcitabine 15Carboplatin 15pembrolizumab 14Specimen Handling 13Paclitaxel 13Bevacizumab 11Radiotherapy 10Nivolumab 10atezolizumab 9Doxorubicin 9Radiation 8Platinum 8Pemetrexed 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Drug Therapy 7Dexamethasone 7Temozolomide 6Rituximab 6Radiotherapy, Intensity-Modulated 6Prednisone 6Ipilimumab 6Cytarabine 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6venetoclax 5Surgical Procedures, Operative 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Antineoplastic Agents × 90 days × Clear all
NCT03651206 2026-06-01

ROCSAN

ARCAGY/ GINECO GROUP

Phase 2/3 Recruiting
138 enrolled
GynecologicSarcoma

Ovarian Carcinosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡